ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Biologics Inc

ADMA Biologics received a Buy rating and a $30.00 price target from Cantor Fitzgerald analyst Kristen Kluska yesterday. According to TipRanks, Klus...

ADMA Biologics (ADMA) Receives a New Rating from Cantor Fitzgerald

ADMA Biologics Inc ( ($ADMA) ) has released its Q3 earnings. Here is a breakdown of the information ADMA Biologics Inc presented to its investors. ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ADMA	$17.18	+5.01%	4.31M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ADMA	$17.18	+5.0%	4.31M
3
4
5
6

ADMA

ADMA

No Data Available

Get ADMA Biologics Inc Data in Excel

Get ADMA Biologics Inc Data in Excel